Min You

6.1k citations
98 papers · 5.0k indexed · h-index 39

Min You

97 papers receiving 4.9k citations

Peers

Min You
Comparison fields: 5 of 130
  • Biotechnology 441
  • Molecular Biology 2.6k
  • Cancer Research 556
  • Immunology 709
  • Biochemistry 227
Replace Eranthie Weerapana with:
Eranthie Weerapana United States
Dianwen Ju China
Ke Ding China
Jakub Gołąb Poland
Chris van Bree Netherlands
Lihe Zhang China
Paolo Paoli Italy
Hyun Kyu Song South Korea
Yili Yang China
Rajani Ravi United States
Min You relative to Eranthie Weerapana United States Eranthie Weerapana's profile →
Citations per field
00.5×1.5×2.1×
Eranthie Weerapana · 1×
Citations per year

Countries citing papers authored by Min You

Since Specialization
Citations

This map shows the geographic impact of Min You's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Min You with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Min You more than expected).

Fields of papers citing papers by Min You

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Min You. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Min You. The network helps show where Min You may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Min You, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Min You Line = papers co-authored together Min You links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20247
2 20245
3 20220
4 202227
5 202212
6 20216
7 20205
8 201847
9 201816
10 201362
11 201267
12 201254
13 201025
14 2008184
15 200587
16 200528
17 1998113
18 199765
19
Evaluation of novel agents that reverse multidrug resistance and mediate cancer chemoprevention.
19951
20 1995180

About Min You

Min You is a scholar working on Biotechnology, Molecular Biology, Surfaces, Coatings and Films, Biochemistry and Molecular Medicine, having authored 98 papers that have together received 5.0k indexed citations. Recurring topics across this work include Cancer Research and Treatments (18 papers), Virus-based gene therapy research (12 papers), Advanced biosensing and bioanalysis techniques (9 papers), Nanoplatforms for cancer theranostics (8 papers), Cancer, Hypoxia, and Metabolism (7 papers), Fibroblast Growth Factor Research (6 papers), RNA Interference and Gene Delivery (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). The work is most often cited by research in Biotechnology (441 citations), Molecular Biology (2.6k citations), Cancer Research (556 citations), Immunology (709 citations) and Biochemistry (227 citations). Min You has collaborated with scholars based in United States, China and Netherlands. Frequent co-authors include Gen‐Sheng Feng, Dehua Yu, Niramol Savaraj, Medhi Wangpaichitr, Kalina Hristova, Edwin Li, Lynn G. Feun, Zhizhuang Joe Zhao, David W. Crabb and Michinaga Matsumoto. Their work appears in journals such as Cancer Research, ACS Applied Materials & Interfaces, Biochemistry, Materials Research Bulletin and Antiviral Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026